BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer
Goldie Y.L. Lui(Fred Hutch Cancer Center), Carla Grandori(Precision for Medicine (United States)), Isabella N. Stork(Fred Hutch Cancer Center), Hallie A. Swan(Precision for Medicine (United States)), Kay E. Gurley(Fred Hutch Cancer Center), Barbara A. Goff(University of Washington), Vijayakrishna K. Gadi(Fred Hutch Cancer Center), Rachele Rosati(Precision for Medicine (United States)), Elizabeth M. Swisher(University of Washington), Franz X. Schaub(Precision for Medicine (United States)), Thomas C. Harding(Genesys (United States)), Christopher J. Kemp(Fred Hutch Cancer Center), Robert L. Diaz, Tan A. Ince(NewYork–Presbyterian Brooklyn Methodist Hospital), Caroline Bridgwater(Precision for Medicine (United States)), Reid Shaw(Precision for Medicine (United States))
Cited by 38
Related Papers
The Myc/Max/Mad Network and the Transcriptional Control of Cell Behavior
|Annual Review of Cell and Developmental Biology|2000|1.3k
Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine
|Cancer Discovery|2017|964
Direct activation of TERT transcription by c-MYC
|Nature Genetics|1999|903
Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion
|Proceedings of the National Academy of Sciences|2000|827
c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I
|Nature Cell Biology|2005|671